Search clinical trials for: Carotuximab (TRC105)

Total 117 results

Chimerix

No longer available

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Glioma

United States
St Stephens Aids Trust

Completed

TMC 125 Blood Levels Study

HIV Infections

United Kingdom
JW Pharmaceutical

Not yet recruiting

PK,PD and DDI of Epaminurad and Naproxen in Healthy Volunteers

Healthy

Korea, Republic of
Tokyo University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer

Esophageal Cancer

Japan
Cognition Pharmaceuticals, LLC

Completed

A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

Multiple Sclerosis | Cognition Disorders

United States
University of Nebraska
Chimerix

Not yet recruiting

A Study of ONC201 for Refractory Meningioma

Meningioma | Refractory Meningioma | Relapsed Meningioma

United States
Chimerix

Active, not recruiting

Oral ONC201 in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Triple Negative Breast Cancer | Endometrial Cancer | Hormone Receptor Positive, HER2 Negative Breast Cancer

United States
RemeGen Co., Ltd.

Recruiting

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

Digestive Cancer

China
Fox Chase Cancer Center
Oncoceutics, Inc.

Terminated

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Endometrial Cancer

United States
Chimerix

No longer available

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Glioma

United States
Fox Chase Cancer Center

Completed

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

Multiple Myeloma | Advanced Solid Tumors

United States
Johnson & Johnson Vision Care, Inc.

Completed

Design Validation of Toric Contact Lenses in Senofilcon A With a Blue-Blocking Chromophore

Visual Acuity

United States
Chimerix

Available

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Glioma | H3 K27M

United States
Peter Anderson

Completed

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Metastatic Neuroendocrine Tumor | Recurrent Neuroendocrine Tumor

United States
Chimerix

Active, not recruiting

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

Glioma

United States
Chimerix

Active, not recruiting

ONC201 in Pediatric H3 K27M Gliomas

Diffuse Intrinsic Pontine Glioma | Glioma, Malignant

United States
Chimerix

Active, not recruiting

ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer

Endometrial Cancer Recurrent

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...

Withdrawn

ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial Gliosarcoma

United States
The Hospital for Sick Children
Tilray

Completed

Cannabinoid Therapy for Pediatric Epilepsy

Epilepsy

Canada
Masonic Cancer Center, University of Minnesota
University of Minnesota

Not yet recruiting

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

Glioblastoma

United States
Tracon Pharmaceuticals Inc.

Completed

Study of TRC102 in Combination With Pemetrexed in Cancer Patients

Neoplasm

United States
Chimerix

Recruiting

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION)

Glioma | H3 K27M

United States, Australia, Canada, Spain, Switzerland, Israel, Germany, Italy, United Kingdom, Korea, Republic of, Netherlands, Denmark, Austria
University of Nebraska

Active, not recruiting

ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Not yet recruiting

Testing ONC201 to Prevent Colorectal Cancer

Familial Adenomatous Polyposis | Colorectal Carcinoma | Colorectal Adenomatous Polyp | Multiple Adenomatous Polyps

United States
Charite University, Berlin, Germany

Completed

InductionChemo-Radio-Antibody-Treatment (ICRAT)

Squamous Cell Carcinoma of the Neck | Squamous Cell Carcinoma of the Head

Germany
Bioksan
Analysis and Research Network, S.L

Completed

Clinical Trial to Demonstrate the Efficacy of a Dietary Supplement in Decreasing Cardiovascular Risk

Low-Moderate Hypercholesterolemia

Spain
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
National Cancer Institute (NCI)

Terminated

Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma

Adult Brain Glioblastoma

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

HIV Infection
University of Alabama at Birmingham
Novartis Pharmaceuticals; Tracon Pharmaceuticals Inc.

Completed

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Breast Cancer

United States
Zhejiang Teruisi Pharmaceutical Inc.

Recruiting

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

CD20-positive B-cell Non-Hodgkin Lymphoma

China
Tibotec Pharmaceuticals, Ireland

Completed

An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).

HIV-1

United States, Canada, France, Belgium, Germany, Spain, Argentina, Chile, Panama, Brazil, Puerto Rico, Thailand, Mexico, Australia
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C223: TMC125 in HIV-1 Infected Subjects

HIV Infection
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Recurrent Adult Brain Neoplasm

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV

United States, France, Argentina, Chile, Mexico, Costa Rica, Panama, Brazil, Puerto Rico, Thailand
UNC Lineberger Comprehensive Cancer Center
Genentech, Inc.; Oncoceutics, Inc.

Recruiting

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Metastasis | Endometrial Cancer

United States
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C187: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Interaction Between TMC125 and Two Antifungal Agents (Fluconazole and Voriconazole), All at Steady-state in Healthy Subjects.

Fungal Infection | HIV | AIDS
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial

HIV Infection
RemeGen Co., Ltd.

Recruiting

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

NSCLC

China
Ira Winer

Recruiting

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Malignant Ovarian Epithelial Tumor | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian... and other conditions

United States
Tibotec Pharmaceuticals, Ireland

Completed

The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

HIV-1

United States, Belgium, Germany, Taiwan, Spain, Mexico, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Korea, Republic of, Russian Federation, Puerto Rico, Luxembourg
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C203: Phase II Randomized (Patients Are Assigned Different Treatments Based on Chance), Placebo Controlled Dose Escalating Trial of TMC125 in HIV-1 Infected Patients

HIV-1 | Anti-Retroviral Agents
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

HIV-1

United States, France, Spain, Portugal, Canada, United Kingdom, South Africa, Argentina, Brazil, Puerto Rico, Thailand, Netherlands, Romania
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

HIV
Tibotec Pharmaceuticals, Ireland

Completed

TMC125-TiDP2-C188: A Phase I, Open-label Trial to Investigate the Pharmacokinetic Effect of Multiple-dose TMC125 on Buprenorphine and Norbuprenorphine Administered in HIV-negative Patients on Stable Buprenorphine/Naloxone Maintenance Therapy.

HIV | Pharmacokinetics
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
IVERIC bio, Inc.

Terminated

Safety Study of Zimura™in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Macular Degeneration
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)

Relapsing Remitting Multiple Sclerosis
University of California, San Francisco
National Institute of Neurological Disorders and Stroke (NINDS); The Chad-Tough... and other collaborators

Recruiting

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Diffuse Midline Glioma, H3 K27M-Mutant | Recurrent WHO Grade III Glioma | WHO Grade III Glioma

United States, Netherlands, Israel, Australia, New Zealand, Switzerland

Search clinical trials for: Carotuximab (TRC105)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations